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Low-molecular-weight AGEs are associated with GFR and ane-
mia in patients with type 2 diabetes.
Background. Advanced glycation end products (AGEs) are
implicated in the development and progression of diabetic
nephropathy. We examined the predictors of low-molecular-
weight (LMW) AGEs in a cross-sectional survey of 604 patients
with type 2 diabetes in a single clinic.
Methods. A clinical history and results of routine blood and
urine testing were obtained for all patients over a 2-year pe-
riod. Fluorescent LMW AGEs were estimated in serum samples
taken concurrently, using an established flow injection method.
Predictors of LMW AGEs were identified using multiple re-
gression analysis.
Results. LMW AGEs were 34% higher in patients with di-
abetes than nondiabetic volunteers from the same community
(P < 0.001). Independent predictors for LMW AGEs in pa-
tients with diabetes were glomerular filtration rate (GFR) and
hemoglobin (both P < 0.001). While patients with renal impair-
ment and anemia had the highest levels of LMW AGEs, both
GFR and hemoglobin remained predictive when patients with
a serum creatinine or hemoglobin within the “normal range”
were analyzed separately. Patients with hyperfiltration had sig-
nificantly lower LMW AGEs than those with normal renal
function. Gender was also a significant independent predictor
of LMW AGEs in patients without anemia. However, LMW
AGEs were not associated with metabolic control or the pres-
ence of macrovascular disease.
Conclusion. Circulating levels of LMW AGEs are elevated
in patients with diabetes, especially those with impaired renal
function or anemia. These findings extend the evidence for an
association between AGEs and progressive renal injury in pa-
tients with type 2 diabetes. Whether LMW AGEs contribute
to, or are a marker of, renal damage needs to be established by
prospective studies.
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Prolonged hyperglycemia and oxidative stress in dia-
betes result in the production and accumulation of ad-
vanced glycation end products (AGEs) [1] in the kidney
[2], the retina [3], and other sites of diabetic microvascu-
lar disease [4]. This heterogenous group of molecules has
a wide range of chemical, cellular, and tissue effects impli-
cated in the development and progression of diabetic end-
organ pathology [5]. Their importance as downstream
mediators of tissue injury in diabetes is demonstrated by
animal studies using inhibitors of advanced glycation to
retard the development of nephropathy without directly
influencing glycemic control [6]. In addition, direct in vivo
exposure to AGEs in rats is able to generate lesions simi-
lar to those seen in the diabetic kidney [7]. In patients with
diabetes, AGE levels may be a better predictor for the de-
velopment of microvascular complications than glycated
hemoglobin, with over a third of the variance in compli-
cations attributable to differences in AGEs in that study
[8]. Although the efficacy of AGE inhibitors remains to
be established in human studies, diets low in AGEs may
be associated with reduced inflammation in patients with
diabetes [9].
Long-lived molecules, such as tissue collagen, are par-
ticularly vulnerable to AGE modification, resulting in
insoluble and relatively inert compounds that accumu-
late progressively with time. Incomplete degradation of
AGE-modified proteins (from tissue or the diet) results
in the formation of low-molecular-weight (LMW) prod-
ucts (LMW AGEs) that accumulate in the blood of
patients with diabetes or renal impairment [10, 11]. In ex-
perimental models, the level of circulating LMW AGEs
parallels the degree of AGE modification within the body
[11]. Since many of the effects of AGEs are mediated fol-
lowing activation of distant AGE-specific receptors, it is
likely that LMW AGEs are also directly pathogenetic.
Indeed, LMW AGEs may have a higher toxic potential
compared with larger AGE-modified proteins [12], being
both stoichiometrically more numerous and free to inter-
act with AGE receptors at distant sites via the circulation.
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LMW AGEs may also rapidly form molecular cross-links
with unmodified protein [13], reducing the time required
for protein to be modified by AGE and therein contribut-
ing to the modification of short-lived molecules such as
lipoproteins.
This study utilizes multivariate analysis to examine cor-
relates of LMW AGEs measured in a large cross-sectional
survey of patients with type 2 diabetes in a single diabetes
clinic. Specifically, we examine for interactions between
numerous clinical and biochemical variables whose asso-
ciations with LMW AGEs have been previously reported
or are biologically plausible.
METHODS
Research design and method
This study was designed as a cross-sectional survey
of patients in current long-term follow-up in a single
diabetes clinic at the Austin and Repatriation Medi-
cal Center (ARMC), Heidelberg, Australia. The ARMC
Diabetes Clinic serves a population of 600,000 in North
Eastern Melbourne. The majority of referrals to the clinic
are from general practitioners requiring assistance with
surveillance and management of the long-term compli-
cations of diabetes. Approximately 20% of the patients
are referred from other sources, including specialty units
within the medical center. None of the participants were
shared with nephrologic services at the time of review.
“Current long-term follow-up” was defined as a clinical
history which included at least three estimations of uri-
nary albumin excretion rate (AER) and having at least
one AER performed within the previous 2 years. This en-
rolment stratagem effectively excluded patients in whom
a diagnosis of diabetes had only recently been made,
when the clinical or biochemical data could be unstable
or of questionable validity. A 2-year window was chosen
to include the review pattern of all patients currently en-
rolled in this clinic (i.e., at least biannual follow-up). Us-
ing this criterion, 604 patients with type 2 diabetes were
identified (82% of all patients with diabetes in this clinic).
Healthy volunteers were recruited from the same com-
munity (N = 120) and samples were screened to exclude
diabetic subjects and those suffering from any significant
medical condition.
Determination of variables
At each routine visit, blood samples were obtained
for standard indices, including serum creatinine, urea,
albumin, fasting blood glucose, fasting lipid profile,
hemoglobin A1c (HbA1c), C-reactive protein (CRP), full
blood count, including hemoglobin, together with trans-
ferrin saturation and ferritin levels. Urinary creatinine,
urea, albumin, and protein were obtained from a 24-hour
collection. Results not obtained in the outpatient clinic
setting (e.g., hospitalized patients or in an emergency set-
ting) were excluded. Where more than one blood test had
been performed during the 2-year period, the most recent
test that included a full blood count was used for analy-
sis. The most recent (prior) routine results for patients
who later died or were referred to a nephrologist during
the 2-year survey period were included in the analysis.
Glomerular filtration rate (GFR) was estimated using the
Modification of Diet in Renal Disease study (MDRD-
6) formula [14]. In a subgroup of patients (N = 382,
64%), GFR was confirmed by the clearance of radiola-
beled diethylenetriamine pentaacetic acid (DTPA). AER
was derived from a 24-hour urinary albumin measure-
ment (not from a spot or any other albumin-to-creatinine
measurement). In addition, the level of albuminuria was
categorically defined from the three most recent AER
measurements. Macroalbuminuria was defined as two of
three AER measurements >200 lg/min. Microalbumin-
uria was defined as two of three AER measurements
>20 lg/min. Normoalbuminuria was defined by two of
three AER measurements <20 lg/min. In accordance
with World Health Organization (WHO) guidelines, ane-
mia was defined as a hemoglobin concentration <13 g/dL
in men and <12 g/dL in women [15]. For statistical anal-
ysis, logarithmic transformations of LMW AGEs, AER,
CRP, fasting blood glucose, and ferritin were performed.
In addition, clinical data, including anthropomorphic
measurements, age, race, gender, age of diagnosis, dura-
tion of diabetes, and length of follow-up, were obtained
from patient records on all patients. A clinical history de-
tailing the presence or absence of specific diabetic com-
plications and treatment modalities was also obtained.
Samples and data were obtained with the patients’ in-
formed consent and the approval of the ARMC Ethics
Committee.
Measurement of serum LMW AGEs
LMW AGEs were measured using serum samples ob-
tained in addition to, but at the same time as, routine
clinical measurements. Their measurement employed an
assay based on the original description by Wrobel et al
[11]. This method has been shown to give a good cor-
relation with serum AGEs measured by immunoassay.
Briefly, 20 uL of serum was deproteinated with 480 lL of
trichloroacetic acid and mixed with 100 lL of chloroform.
The resulting aqueous phase was injected directly into a
carrier stream (deionized water) in which total AGE fluo-
rescence (370/440 nm) was measured using a Waters 470
fluorescence spectrophotometer (Waters, Milford, MA,
USA). Injection volume was standardized using the ab-
sorbance at 280 nm by an ultraviolet detector placed in
series. Samples were assayed in triplicate. The content
of LMW AGEs was expressed as arbitrary units (AU)
defined by the ratio of the area under the fluorescence
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curve divided by the area under the A280 curve, normal-
ized to the values derived following exhaustive enzymatic
hydrolysis of AGE albumin.
Statistical methods
Continuous data are expressed as mean ± SEM except
where specified. Differences in continuous variables were
compared using Student t tests (two groups) or one-way
analysis of variance (ANOVA) (three or more groups).
Differences in categorical variables were compared the
using chi-square analysis. Pearson correlation was used to
analyze univariate associations between continuous vari-
ables. Multivariate analysis utilized multiple regression
and analysis of covariance (ANCOVA) to model the in-
dependent predictors of the level of LMW AGEs.
RESULTS
Outpatient population
A total of 604 patients with type 2 diabetes were in
current long-term follow-up in our center. The study in-
cluded 336 men (56%) and 268 women who had been fol-
lowed up for a median of 4.5 years (range 1 to 28 years).
The mean age was 65.1 ± 0.5 years (range 29 to 86 years).
Over 95% of patients were of Caucasian descent and
the study included no African American patients. The
median duration of diabetes was 10.5 years, with a me-
dian of 6 years spent in the ARMC clinic, attending on
average every 9 months. Thirty percent had microalbu-
minuria and 12% macroalbuminuria. The mean HbA1c
was 7.8 ± 0.1%. The mean estimated GFR was 72.3 ±
1.1 mL/min/1.73 m2 with 25% of men and 24% of
women having moderate renal impairment (GFR 30 to
60 mL/min/1.73 m2) and 7% of men and 8% of women
severe renal impairment (GFR <30 mL/min/1.73 m2).
Forty-five percent of patients had documented vascu-
lar disease (34% having a history of ischemic heart dis-
ease, 15% cerebrovascular disease, and 14% peripheral
vascular disease). Fifty percent of patients in this sur-
vey were obese [body mass index (BMI) >30 kg/m2]. In
this cohort, 42% of patients with type 2 diabetes also
received insulin as an adjunct to their other treatments
for glycemic control. Most patients also received anti-
hypertensive therapy (77%), the majority (84%) with
an angiotensin-converting enzyme (ACE) inhibitor and
59% also received a lipid-lowering agent.
LMW AGEs in patients with diabetes
LMW AGEs were on average 34% higher in patients
with diabetes than in healthy volunteers matched for age
and gender from the same community (diabetes 9.4 AU;
nondiabetic 7.0 AU, P < 0.001). Twenty-seven percent of
patients with diabetes had levels of LMW AGEs greater
than 12 AU, compared to 6% of patients without diabetes.
No patient without diabetes had levels of LMW AGEs
Table 1. Additional clinical and biochemical associations with
low-molecular-weight (LMW) advanced glycation end products
(AGEs) in patients with type 2 diabetesa
Univariate Adjusted
Variable P value P valueb
Age <0.0001 0.15
Gender <0.01 0.08
Diabetes duration <0.01 0.48
Anti-renin-angiotensin system therapy <0.02 0.35
Insulin treatment 0.04 0.56
Congestive heart disease history 0.01 0.27
Cerebrovascular disease history 0.05 0.41
Vascular disease (congestive heart disease, <0.01 0.31
cerebrovascular disease, or peripheral
vascular disease)
Total cholesterol <0.01 0.14
Low-density lipoprotein cholesterol 0.01 0.15
Albumin excretion rate 0.02 0.85
Serum iron <0.01 0.48
aThere were no significant univariate associations between AGE and
body mass index (BMI), blood pressure (systolic, diastolic, mitogen-activated
protein or antihypertensive treatment), peripheral vascular disease, retinopathy,
smoking, hypolipidemic treatment, triglycerides, high-density lipoprotein,
fasting blood glucose, hemoglobin A1c, C-reactive protein, ferritin, transferring
saturation, or kidney size.
bAdjusted P values refer to analysis of covariance (ANCOVA) adjusted for
glomerular filtration rate (GFR) and hemoglobin.
greater than 25 AU, compared to 3% of patients with
diabetes and normal renal function (GFR >60 mL/min/
1.73 m2) and 12% of patients with diabetes and renal
impairment.
Predictors of LMW AGEs
There were several univariate associations with LMW
AGEs in patients with type 2 diabetes (Table 1). How-
ever, multivariate analysis revealed that only GFR (P <
0.0001) and hemoglobin (P = 0.001) remained as sig-
nificant independent predictors of LMW AGE levels.
When GFR and hemoglobin were stratified into binary
variables (GFR <60 mL/min/1.73 m2 or >60 mL/min/
1.73 m2; anemia or normal hemoglobin), patients with-
out significant renal impairment (GFR >60 mL/min/
1.73 m2) and with normal hemoglobin levels had the low-
est level of LMW AGEs. All other three groups had sig-
nificantly higher levels than this group. The highest LMW
AGEs were observed in anemic patients with moderate
to severe renal impairment. Notably, the effect of ane-
mia and renal impairment were approximately parallel
[i.e., there was no evidence of statistical interaction (P =
0.53)]. No other variables were independently associated
with LMW AGEs in the population as a whole.
The independent effect of GFR
GFR was the strongest determinant of LMW AGEs
levels. The correlation between LMW AGEs and GFR
was similar whether GFR was by derived from iso-
topic measurements (P < 0.0001) or estimated using the
MDRD-6 formula (P < 0.0001), reflecting the utility of
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Fig. 1. Low-molecular-weight (LMW) advanced glycation products
(AGEs) are independently associated with glomerular filtration rate
(GFR) and anemia in patients with diabetes of both genders. ∗Gender
difference P < 0.05.
this formula in this setting [16]. Patients with the mod-
erate to severe renal impairment (GFR <60 mL/min/
1.73 m2) had significantly higher LMW AGEs levels that
patients with preserved renal function (Fig. 1). While this
fact has been known for over 10 years [13, 17], the influ-
ence of GFR was not confined to those with moderate
to severe renal impairment. Indeed, the relationship be-
tween GFR and LMW AGEs appeared continuous across
the whole range of renal function. Notably, even in pa-
tients with a serum creatinine within the “normal” range
(serum creatinine <0.11 mmol/L), GFR remained a sig-
nificant predictor of LMW AGEs (P < 0.01).
The continuous nature of the relationship between
GFR and LMW AGEs was further demonstrated by
the fact that hyperfiltration (arbitrarily defined as GFR
>130 mL/min/1.73 m2) was associated with significantly
lower LMW AGEs levels than seen in patients with nor-
mal renal function (GFR 90 to 120 mL/min/1.73 m2). No-
tably, only 11% of patients with a GFR > 130 mL/min/
1.73 m2 had LMW AGEs levels greater than 12 AU,
compared to twice that number with a “normal” GFR
(90 to 130 mL/min/1.73 m2) (23%) and nearly twice that
number again in patients with renal impairment (GFR
<60 mL/min/1.73 m2) (39%). Indeed, the sole patient
with hyperfiltration and LMW AGEs >12 AU had ane-
mia and there were no hyperfiltering patients with normal
hemoglobin and LMW AGEs >12 AU.
The independent effect of anemia
Patients with anemia had higher LMW AGEs than
patients with hemoglobin levels in the normal gender-
specific range, at different levels of GFR (P = 0.02) and
without significant interaction (P = 0.98) (Fig. 1). How-
ever, this relationship was not confined to patients with
anemia. The continuous nature of the relationship be-
tween hemoglobin and LMW AGEs was apparent across
the whole range of hemoglobin concentrations (P =
0.001, adjusted for GFR) and was also seen in patients
with a hemoglobin level within the normal range for each
gender (P < 0.01).
The effect of gender
In our survey, women with type 2 diabetes had LMW
AGEs levels 17% higher than men (P < 0.01). However,
the association between gender and LMW AGEs was
complex. Overall, female gender showed a nonsignificant
trend toward an association with LMW AGEs after ad-
justing for GFR and hemoglobin (P = 0.08). However,
within the subgroup of patients without anemia, women
had significantly higher LMW AGEs than men (P < 0.01)
(Fig. 1). In this subgroup, the gender difference was signif-
icant across all strata of GFR (interaction P = 0.53) and
there was no significant interaction. By contrast, there
was no significant gender difference in anemic patients,
irrespective of GFR (P = 0.49). Although the increased
LMW AGE levels in women without anemia could be
largely explained by their lower hemoglobin levels, using
a multivariate model predicting LMW AGEs in patients
without anemia incorporating both hemoglobin and GFR
as continuous variables, gender remained a significant in-
dependent predictor of LMW AGE levels. This finding
was not influenced by amenorrhea, as menstrual status
per se did not independently influence LMW AGEs lev-
els in women. Neither was this finding influenced by iron
stores (which are the main determinant of gender differ-
ences in hemoglobin levels), further suggesting that the
influence of gender, in this subgroup, was independent to
hemoglobin.
DISCUSSION
Glycation oxidatively modified proteins that accumu-
late in diabetes can form large aggregates because of
covalent cross-linking or increased surface hydropho-
bicity. Unless repaired or removed from cells, these
proteins threaten cell viability. Most damaged proteins
appear to undergo selective proteolysis, primarily by the
proteasome [18]. The normal proteasomal processing of
cellular protein (by macrophages, lysosomal-containing
cells, or extracellular proteolytic pathways) is highly ef-
ficient and virtually complete, leading to the release of
bioavailable amino acids and dipeptides [19]. However,
AGE modification of a protein renders it resistant to com-
plete proteolytic digestion. For example, most serine pro-
teases depend upon the lysine residues for activity, which
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are masked by AGE modification. In addition, inter- and
intramolecular cross-links are both enzymatically stable
and prevent access to scission sites. As a result, incom-
plete degradation of AGE-modified protein (from tissue
or the diet) results in the formation of LMW degrada-
tion products (LMW AGEs) incorporating these AGE
modifications.
The precise chemical nature of circulating LMW AGEs
remains to be established. Studies by Thornalley et al
[10] suggest that LMW AGEs are in fact “free AGEs”
rather than “AGE peptides,” as they were unable to de-
tect any significant increase in the AGE content of a
LMW plasma ultrafiltrate following exhaustive enzymic
hydrolysis [10]. The so-called “free” form of pentosidine
may be one of such LMW AGEs [20]. Although complete
(acid) hydrolysis was not performed by Thornalley et al
[10], it is likely that LMW AGEs represent the termi-
nal degradation products of proteasomal processing and
intestinal digestion of ingested AGE-modified proteins,
be they oligopeptides or modified amino acids. Function-
ally, LMW AGEs may be considered biologically “un-
available” as they are completely resistant to enzymatic
digestion. In addition, the predominant fluorophores
identified by our assay remains to be established, al-
though it is likely that most are hydroimidazolone AGEs
[10]. However, as most known AGE fluorophores are sta-
ble and chemically unreactive, it seems more likely that
AGE fluorescence in our assay is a marker for the pres-
ence of other free AGEs with greater toxic potential or
(unmeasured) toxic AGE intermediates [1].
LMW AGEs may be considered a marker of the de-
gree of tissue AGE modification [11]. Consistent with
this premise, the observed difference in LMW AGEs be-
tween patients with diabetes and the nondiabetic con-
trols was comparable to differences measured for other
compounds of AGE, including Ne-carboxymethyl lysine
(CML) and imidazoles [21, 22]. However, LMW AGEs
may also be able to independently induce changes in re-
nal structure and function. Evidence now points to the
pivotal role of activation of multiligand AGE-specific re-
ceptors in the development and progression of diabetic
nephropathy [5]. Although the LMW fraction of serum
contains less than 10% of some circulating AGEs [10],
LMW AGEs are stoichiometrically more numerous than
AGE-modified proteins and, unlike AGE-modified pro-
teins, are easily filtered through the glomerular barrier
and come into contact with the proximal tubular epithe-
lial cells where they are actively absorbed [23]. In addi-
tion, if the majority of AGE-mediated injury occurs via
activation of multiligand AGE receptors, it is possible to
speculate that the accumulation of AGEs, through a vari-
ety of pathways and in a variety of molecular forms, may
be similarly pathogenic. Indeed, AGEs with measurable
AGE receptor binding affinity may be produced in vitro,
regardless of the reducing sugar or the precise chemi-
cal modification [24]. Given that Maillard chemistry pro-
duces a hugely diverse range of heterocyles, polymers and
advanced Maillard products, the precise chemical modifi-
cation may be of less consequence than its binding affinity
and ability to activate pathogenic pathways.
While advanced glycation is driven by hyperglycemia
and increased oxidative stress, GFR and hemoglobin ap-
pear to be the most important determinants of LMW
AGEs levels in patients with diabetes. This most likely
reflects the clearance role of the kidney in the removal
of LMW AGEs. While de novo AGE formation may also
be accelerated in uremia due to carbonyl and oxidative
stress, we demonstrate that the relationship between re-
nal function and AGE is not confined to patients with re-
nal impairment but is continuous across the whole range
of renal function in our population. Notably, the relation-
ship between LMW AGEs and renal function was demon-
strable even in patients with a serum creatinine within
the “normal range.” This association further underlines
the importance of an estimated GFR in the assessment
of the clinical status of diabetic patients. In addition, pa-
tients with hyperfiltration had the lowest level of LMW
AGEs, possibly acting to protect the body from the aug-
mented production of AGEs associated with diabetes.
However, any decline in renal function, even within the
normal range, appears to contribute to the accumulation
of pathogenic LMW AGEs in diabetes. Given that the
risk of complications also increases substantially with re-
nal impairment, the association between GFR and LMW
AGEs may provide a possible mechanistic link.
The close association between declining hemoglobin
and LMW AGEs has not been previously documented.
It is not clear how hemoglobin levels influence either
the production or clearance of LMW AGEs. It does not
appear to be confounded by iron stores or systemic in-
flammation (as measured by CRP), as neither of these
variables correlated LMW AGEs. Reduced tissue oxy-
genation associated with anemia may contribute to the
formation of AGEs. It is also conceivable that both
hemoglobin and LMW AGEs are markers of tubular
injury [25]. However, the strength of this association,
demonstrated even in patients with “normal” renal func-
tion and hemoglobin levels, suggests a more pivotal in-
teraction. Given the continuous relationship between
hemoglobin levels and renal outcome in patients with
type 2 diabetes [26], this association deserves further
analysis.
Increased levels of LMW AGEs were clearly associ-
ated with the presence of macrovascular disease in our
study, although this association was eliminated after ad-
justing for renal function. Similar results have recently
been described by Sharp, Rainbow, and Mukherjee [27]
and Beisswenger et al [28], suggesting that fluorescent
AGEs are not independently associated with the pres-
ence of diabetic complications in patients with type 2
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diabetes. Against this, other smaller studies have found
a link between fluorescent serum AGEs and coronary
artery disease in type 2 diabetes, although these studies
did not adjust for GFR in patients with “normal renal
function” [20]. Nonetheless, diabetic patients with a low
hemoglobin or reduced GFR are at increased risk of car-
diovascular disease and death [26] and both of these risk
factors are closely linked to levels of LMW AGEs. It is
conceivable that the some of the risk for macrovascular
disease associated with renal impairment may be directly
attributable to AGEs. Correcting for renal function in
this setting, would negate the potential role that LMW
AGEs might play as uremic toxins [29].
CONCLUSION
Circulating LMW AGEs are elevated in patients with
diabetes, especially those with impaired renal function or
anemia. The relationship between levels of LMW AGEs,
GFR, and anemia was present even within the normal
range of these parameters. These findings provide clinical
support for the association between LMW AGEs and
progressive renal injury in patients with type 2 diabetes.
Longitudinal studies are still required to establish a cause
or effect relationship.
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